Literature DB >> 17296558

Disruption of the CRF/CRF1 receptor stress system exacerbates the somatic signs of opiate withdrawal.

Francesco Papaleo1, Pierre Kitchener, Angelo Contarino.   

Abstract

Escape from the extremely stressful opiate withdrawal syndrome may motivate opiate seeking and taking. The corticotropin-releasing factor receptor-1 (CRF1) pathway mediates behavioral and endocrine responses to stress. Here, we report that genetic inactivation (CRF1-/-) as well as pharmacological antagonism of the CRF/CRF1 receptor pathway increased and prolonged the somatic expression of opiate withdrawal. Opiate-withdrawn CRF1-/- mice also showed aberrant CRF and dynorphin expression in the paraventricular nucleus of the hypothalamus (PVN) and the striatum, indicating profound impairments in stress-responsive brain circuitry. Intake of nonstressful amounts of corticosterone effectively reduced the exaggerated somatic reactions of CRF1-/- mice to opiate withdrawal. Exogenous corticosterone also restored "wild-type-like" patterns of CRF and dynorphin gene expression in the PVN and the striatum of opiate-withdrawn CRF1-/- mice, respectively. The present findings unravel a key role for the hypothalamus-pituitary-adrenal (HPA) system and brain extra-hypothalamic CRF/CRF1 receptor circuitry in somatic, molecular, and endocrine alterations induced by opiate withdrawal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296558     DOI: 10.1016/j.neuron.2007.01.022

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  20 in total

1.  CRF₂ mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats.

Authors:  Javier Navarro-Zaragoza; Cristina Núñez; Jessica Ruiz-Medina; M Luisa Laorden; Olga Valverde; M Victoria Milanés
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Increased motivation to eat in opiate-withdrawn mice.

Authors:  Khalil Rouibi; Angelo Contarino
Journal:  Psychopharmacology (Berl)       Date:  2011-12-30       Impact factor: 4.530

3.  Corticotropin-releasing factor receptor 2-deficiency eliminates social behaviour deficits and vulnerability induced by cocaine.

Authors:  Nadège Morisot; Romain Monier; Catherine Le Moine; Mark J Millan; Angelo Contarino
Journal:  Br J Pharmacol       Date:  2018-03-13       Impact factor: 8.739

Review 4.  Corticotropin releasing factor: a key role in the neurobiology of addiction.

Authors:  Eric P Zorrilla; Marian L Logrip; George F Koob
Journal:  Front Neuroendocrinol       Date:  2014-01-20       Impact factor: 8.606

5.  Glucocorticoid Homeostasis in the Dentate Gyrus Is Essential for Opiate Withdrawal-Associated Memories.

Authors:  Daniel García-Pérez; Szilamer Ferenczi; Krisztina J Kovács; M Luisa Laorden; M Victoria Milanés; Cristina Núñez
Journal:  Mol Neurobiol       Date:  2016-10-11       Impact factor: 5.590

6.  CRF1 receptor-deficiency induces anxiety-like vulnerability to cocaine.

Authors:  Nadège Morisot; Mark J Millan; Angelo Contarino
Journal:  Psychopharmacology (Berl)       Date:  2014-04-01       Impact factor: 4.530

Review 7.  Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention.

Authors:  Marian L Logrip; George F Koob; Eric P Zorrilla
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

8.  Disruption of the CRF(2) receptor pathway decreases the somatic expression of opiate withdrawal.

Authors:  Francesco Papaleo; Sandy Ghozland; Manuela Ingallinesi; Amanda J Roberts; George F Koob; Angelo Contarino
Journal:  Neuropsychopharmacology       Date:  2008-02-20       Impact factor: 7.853

Review 9.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Authors:  M R Bruchas; B B Land; C Chavkin
Journal:  Brain Res       Date:  2009-08-28       Impact factor: 3.252

Review 10.  Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation.

Authors:  Catherine M Cahill; Wendy Walwyn; Anna M W Taylor; Amynah A A Pradhan; Christopher J Evans
Journal:  Trends Pharmacol Sci       Date:  2016-09-23       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.